final program.qxd - Parallels Plesk Panel

More documents

Recommendations

Info

WEDNESDAY JUNE 21, 2006 - MERCREDI 21 JUIN 2006 • FP 1.2 • FP 1.3 • FP 1.4 • FP 1.5 • FP 1.6 • FP 1.7 • FP 1.8 • FP 1.9 • FP 1.10 • FP 1.11 Natural Suppressors, HIV-1 Viral Suppression in the Absence of Therapy MOHAMMAD SAJADI, BALTIMORE - USA An in vitro System for HIV-1 Selective Transmission using Human Genital Epithelial cells ZHIWEI WU, NANJING - CHN V1V2 loop length variation during HIV-1 Infection MARCEL CURLIN, SEATTLE - USA Generic Screening Test for HIV Infection FRANÇOIS SIMON, ROUEN - FRA Analysis of Plasma Cytokines in Immunological and Virological Discordant HIV-1 Infected Patients by Microarray System: a pilot study DESHRATN ASTHANA, MIAMI - USA HIV-1 Subtype C Viruses Rapidly Develop K65R Resistance to Tenofovir in Cell Culture MARK WAINBERG, MONTREAL - CAN Detection of Low Frequency HIV-1C Drug Resistant Variants in Treatment Exposed Patients HARRIET OKATCH, BOSTON - USA HCV-Associated B Cell Clonalities in the Liver do not Carry the t(14;18) Chromosomal Translocation DOMENICO SANSONNO, BARI - ITA Replication-Competent Platforms for Lassa Fever Vaccine Design IGOR LUKASHEVICH, BALTIMORE - USA Bats as Potential Reservoirs for Ebola Virus XAVIER POURRUT, FRANCEVILLE - GAB “ Focusing FIRST on PEOPLE “ 10 w w w . i s h e i d . c o m
THURSDAY JUNE 22, 2006 - JEUDI 22 JUIN 2006 • 08.30 - 10.30 SESSION VAUBAN AMPHITHEATER NEW ANTIRETROVIRAL DRUGS - NOUVEAUX ANTI-RÉTROVIRAUX CHAIRPERSONS: JACQUES REYNES, MONTPELLIER - FRA & JOEP LANGE, AMSTERDAM - NED • OP 4.1 • OP 4.2 • OP 4.3 • OP 4.4 • OP 4.5 • FP 0.1 • FP 0.2 New Antiretrovirals in the Pipeline: from Already Known Targets to Integrase Inhibitors Les anti-rétroviraux en développement : des inhibiteurs de cibles déjà connues aux inhibiteurs d’intégrase STEFANO VELLA, ROMA - ITA Development of AVX754 - Développement du AVX754 SUSAN COX, RICHMOND - AUS Update on TMC114 - Actualités sur TMC114 DIEGO MIRALLES, MECHELEN - BEL Update on Maraviroc Studies - Le point des études sur le Maraviroc CHRIS HITCHCOCK, SANDWICH - GBR Recent Data on PA457 Maturation Inhibitor Données récentes sur l’inhibiteur de maturation, PA457 DAVID MARTIN, MARYLAND - USA Thiovir Exhibits Broad-Spectrum Antiviral Activity Against Human and Avian Influenza Viruses, Human Immunodeficiency Viruses, and Herpes Simplex Viruses - Thiovir démontre une activité antivirale large spectre contre les virus de la grippe aviaire humaine, les VIH et les HSV SHANI WANINGER, SAN DIEGO - USA Preclinical Development of a Novel Long-Lasting HIV-1 Fusion Inhibitor - Développement pré-clinique d'un nouvel inhibiteur de fusion du VIH-1 à libération prolongée DONG XIE, CHONGQING - CHN 10.30 - 11.00 Break, Posters, Exhibition - Pause, posters, exposition • 11.00 - 12.30 SYMPOSIUM VAUBAN AMPHITHEATER HOW TO MANAGE GETTING OLDER WITH HIV - BIEN VIEILLIR AVEC LE VIH CHAIRPERSONS: CHRISTINE KATLAMA, PARIS - FRA & ALAIN LAFEUILLADE, TOULON - FRA • SS 3.1 • SS 3.2 • SS 3.3 Brain and HIV Cerveau et VIH JACQUES GASNAULT, KREMLIN-BICÊTRE - FRA Long-Term Cardiovascular Troubles of HIV Patients Troubles cardiovasculaires à long terme des patients VIH DAVID ZUCMAN, SURESNES - FRA Cancer and HIV - Cancer et VIH CHRISTINE KATLAMA, PARIS - FRA “ Focusing FIRST on PEOPLE “ 11 w w w . i s h e i d . c o m
Page 2 and 3: EDITORIAL Dear Madam, Dear Sir, It
Page 4 and 5: PRACTICAL INFORMATION - INFORMATION
Page 6 and 7: PROGRAM AT A GLANCE “ Focusing FI
Page 8 and 9: WEDNESDAY JUNE 21, 2006 - MERCREDI
Page 12 and 13: THURSDAY JUNE 22, 2006 - JEUDI 22 J
Page 14 and 15: THURSDAY JUNE 22, 2006 - JEUDI 22 J
Page 16 and 17: FRIDAY JUNE 23, 2006 - VENDREDI 23
Page 18 and 19: POSTERS PRESENTATIONS - PRESENTATIO
Page 32 and 33: The hospital reform in progress may
Page 34 and 35: OP 1.3 Public Health and Social Sci
Page 36 and 37: OP 2.1 Research Priorities in HIV :
Page 38 and 39: OP 2.3 Research Priorities In HIV I
Page 40 and 41: OP 3.2 Interactions between HSV and
Page 42 and 43: OP 3.4 Fertility options in HIV-inf
Page 44 and 45: OP 3.5 Non-AIDS defining cancers in
Page 46 and 47: OP 4.3 Update on TMC114 - Actualit
Page 48 and 49: OP 4.5 Recent data on PA-457 Matura
Page 50 and 51: OP 5.3 Immunology - Summary of adva
Page 52 and 53: OP 6.2 Molecular Epidemiology of HI
Page 54 and 55: In 1995 HIV started to spread rapid
Page 56 and 57: Given the high HIV prevalence in ID
Page 58 and 59: OP 6.4 The Epidemiology of HIV & ST
Page 60 and 61:
OP 7.3.1 We must switch early patie
Page 62 and 63:
OP 7.4.2 Entry inhibitors have to b
Page 64 and 65:
OP 8.2 West Nile Virus Infection in
Page 66 and 67:
First, the origin of primary introd
Page 68 and 69:
To reduce the amount of virus that
Page 70 and 71:
OP 9.1 New Developments in the Trea
Page 72 and 73:
OP 9.3 Future options in non respon
Page 74 and 75:
the consensus interferon dose (25,2
Page 76 and 77:
interferon maintenance therapy in d
Page 78 and 79:
26) Kaiser S, Hass HG, Gregor M. Su
Page 80 and 81:
OP 10.1 Progress in Microbicide Dev
Page 82 and 83:
OP 10.3 Current Advances in HIV Vac
Page 84 and 85:
dysmetabolic, functional, or organi
Page 86 and 87:
Orphans Forty-three percent of the
Page 88 and 89:
PP 1.4 Pradip Timilsena, Laxmi Pras
Page 90 and 91:
PP 1.6 Epidemiological aspects of M
Page 92 and 93:
PP 1.8 HIV transmission in The Gamb
Page 94 and 95:
PP 1.10 Evaluation of Prevalence an
Page 96 and 97:
PP 1.12 Co-morbidity of HIV, Hepati
Page 98 and 99:
PP 1.14 Screening for HIV-infection
Page 100 and 101:
PP 1.16 Low performance of HIV-1 se
Page 102 and 103:
PP 1.18 The spread of HIV-1 resista
Page 104 and 105:
PP 1.20 Study of the anti-HIV recom
Page 106 and 107:
PP 1.22 Comparative investigation o
Page 108 and 109:
PP 1.24 Foreign Citizens Admitted t
Page 110 and 111:
PP 1.26 Morbidity pattern of PLWA r
Page 112 and 113:
PP 1.28 Incidence of Atypical Mycob
Page 114 and 115:
PP 1.29 Developing Partnerships Bet
Page 116 and 117:
PP 1.31 Pakistani Youth and their R
Page 118 and 119:
PP 1.33 Model based on a quantum al
Page 120 and 121:
PP 2.2 Analysis of Full-length HIV-
Page 122 and 123:
PP 2.4 The Cobas Ampliprep/Cobas Ta
Page 124 and 125:
PP 2.6 Mutations and Polymorphisms
Page 126 and 127:
PP 2.8 Differences in the phenotypi
Page 128 and 129:
PP 2.10 Biochemical Characterizatio
Page 130 and 131:
Upon 60 minutes contact of BVDV spi
Page 132 and 133:
PP 2.13 Assessing the Contribution
Page 134 and 135:
PP 2.15 Correlation between circula
Page 136 and 137:
PP 2.17 Interface targeting peptide
Page 138 and 139:
PP 2.19 HIV-1 gene expression: less
Page 140 and 141:
PP 2.21 Vesical Cancer and Papillom
Page 142 and 143:
PP 3.2 Is Age a Complicating Factor
Page 144 and 145:
PP 3.4 Reversible HIV associated en
Page 146 and 147:
PP 3.6 Mycobacterium Ulcerans Cutan
Page 148 and 149:
PP 3.8 A Clinical Study Of 60 Patie
Page 150 and 151:
PP 3.9 HIV and Tuberculosis: Partne
Page 152 and 153:
PP 3.11 Clinicopathological compari
Page 154 and 155:
PP 3.13 Crohn's disease onset in a
Page 156 and 157:
PP 3.15 Ocular manifestations occur
Page 158 and 159:
PP 3.17 Bladder carcinoma observed
Page 160 and 161:
PP 3.19 Increasing concerns related
Page 162 and 163:
PP 3.21 Glucose intolerance and ins
Page 164 and 165:
PP 3.23 Proviral DNA and plasma vir
Page 166 and 167:
PP 3.25 Frequency, monitoring, clin
Page 168 and 169:
PP 3.27 HIV-positive cases as part
Page 170 and 171:
PP 3.29 The Effects of a Supervised
Page 172 and 173:
PP 3.31 Prevalence of depression am
Page 174 and 175:
PP 3.33 Rhinopharyngeal carcinoma w
Page 176 and 177:
PP 3.35 Large vessel damage due to
Page 178 and 179:
PP 3.37 No Interference between Syp
Page 180 and 181:
PP 3.39 Faecal flora, diarrhoea ass
Page 182 and 183:
PP 4.2 Triple therapy adherence in
Page 184 and 185:
In a hierarchical multiple regressi
Page 186 and 187:
PP 4.5 A Prospective Study of Antir
Page 188 and 189:
PP 4.7 Telephone-Based Coping Impro
Page 190 and 191:
PP 4.9 The significantly different
Page 192 and 193:
PP 4.11 Self-Evaluation Investigati
Page 194 and 195:
PP 4.13 Treatment of Kaposi's sarco
Page 196 and 197:
PP 4.15 Pharmacokinetic Interaction
Page 198 and 199:
PP 4.17 Human immunodeficiency viru
Page 200 and 201:
PP 4.19 Much More Sure than 2 Years
Page 202 and 203:
PP 4.21 No evidence of reduced viro
Page 204 and 205:
PP 4.23 The increased liver toxicit
Page 206 and 207:
PP 4.25 Rapid Oral Desensitization
Page 208 and 209:
PP 5.1 Rational design of HCV antig
Page 210 and 211:
PP 5.3 Immune restoration levels un
Page 212 and 213:
PP 5.5 Fulminant Candida albicans p
Page 214 and 215:
PP 5.7 Chronic hepatitic C-prompted
Page 216 and 217:
PP 5.9 Chronic HBV infection associ
Page 218 and 219:
PP 6.2 Broadly protective immunity
Page 220 and 221:
PP 6.4 Chikungunya arthritis sequel
Page 222 and 223:
PP 6.5 Experimental determination o
Page 224 and 225:
PP 6.7 Emerging Arboviruses in Turi
Page 226 and 227:
PP 6.9 Ocular LOA-LOA Infection in
Page 228 and 229:
PP 6.11 Prevalence of Carriers of M
Page 230 and 231:
PP 6.13 Evaluation of the Prevalenc
Page 232 and 233:
PP 6.15 Assessment of need of Patie
Page 234 and 235:
PP 6.17 Community-acquired septicem
Page 236 and 237:
PP 6.19 Multiple sclerosis managed
Page 238 and 239:
PP 6.21 A serious staphylococcal kn
Page 240 and 241:
PP 6.23 Comparison between Secretor
Page 242 and 243:
PP 6.25 Real- Time PCR and Flow Cyt
Page 244 and 245:
FP 0.2 Preclinical Development of a
Page 246 and 247:
FP 0.4 Primary Resistance of a Nove
Page 248 and 249:
FP 1.1 In Vivo Emergence of RANTES-
Page 250 and 251:
Conclusion:Patients with HIV-1 infe
Page 252 and 253:
FP 1.4 V1V2 loop length variation d
Page 254 and 255:
FP 1.6 Analysis of plasma cytokines
Page 256 and 257:
FP 1.8 Detection of low frequency H
Page 258 and 259:
FP 1.10 Replication-Competent Platf
Page 260 and 261:
FP 2.1 Long-term non-progression in
Page 262 and 263:
FP 2.3 HAART in Sub-Saharan countri
Page 264 and 265:
FP 2.5 Morbidity and mortality by b
Page 266 and 267:
FP 2.6 Tolerability of antiretrovir
Page 268 and 269:
FP 2.8 Radata - An internet-based s
Page 270 and 271:
FP 3.2 Glycosylated recombinant sim
Page 272 and 273:
FP 3.4 Therapeutic Tat-Vaccination
Page 274 and 275:
PL 2 HIV & AIDS Research: The Light
Page 276 and 277:
SS 1.1 The importance of HIV drug r
Page 278 and 279:
SS 1.3 Virtual phenotype and Clinic
Page 280 and 281:
SS 2.1 The Lessons we have Learned
Page 282 and 283:
SS 5.2 HIV-associated facial lipoat
Page 284 and 285:
SS 6.1 How to improve the use of ne
Page 286 and 287:
SS 6.3 Tipranavir is a Potent Prote
Page 288 and 289:
ABBOTT FRANCE Abbott is a global, b
Page 290 and 291:
BOEHRINGER INGELHEIM The Boehringer
Page 292 and 293:
IVAGEN IVAGEN SA, a biotechnology c
Page 294 and 295:
ROCHE Headquartered in Basel, Switz
Page 296 and 297:
Putting knowledge into practice VIR
Page 298:
NOTES “ Focusing FIRST on PEOPLE
show all

final program.qxd - Parallels Plesk Panel

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?